此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

PK and Safety After C-Section

2026年10月29日 更新者:Heron Therapeutics

A Phase 2, Open-Label Study of the Pharmacokinetics and Safety of HTX-011 Administered Postpartum to Women Undergoing a Planned Caesarean Section

The main goal of the study was to measure the amount of the active ingredients and other components of HTX-011 in plasma and expressed breast milk over time following postpartum administration in women undergoing a planned C-section. The study also looked at the safety of HTX-011 in these women.

研究概览

研究类型

介入性

注册 (实际的)

25

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Alabama
      • Sheffield、Alabama、美国、35660
        • Helen Keller Hospital
    • California
      • San Diego、California、美国、92123
        • Sharp Mary Birch Hospital for Women and Newborns
    • North Carolina
      • Durham、North Carolina、美国、27710
        • Duke University Medical Center
    • Pennsylvania
      • Pittsburgh、Pennsylvania、美国、15213
        • UPMC Magee-Womens Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

女性

描述

Inclusion Criteria:

  • Is expected, at the time of Screening visit, to deliver a single neonate.
  • Is scheduled to undergo a planned C-section surgery with a low transverse skin incision (eg, Pfannenstiel).
  • Has American Society of Anesthesiologists (ASA) Physical Status of I, II, or III.
  • Agrees to practice abstinence or use double-barrier contraception in the event of sexual activity and commits to the use of an acceptable form of birth control for 30 days after HTX-011 administration.
  • Agrees to refrain from the use of breast milk from this pregnancy in any manner.

Exclusion Criteria:

  • Has planned to breastfeed her neonate at any time during the 28-day period after HTX-011 administration.
  • Has had a prior full-term pregnancy with unsuccessful breast milk expression.
  • Has a planned concurrent surgical procedure.
  • Has a contraindication or a known or suspected history of hypersensitivity or clinically significant idiosyncratic reaction to required study medications.
  • Has been administered bupivacaine within 5 days prior to the scheduled surgery.
  • Has been administered any local anesthetic within 72 hours prior to the scheduled surgery.
  • Has been administered systemic steroids within 5 half-lives or 10 days prior to administration of study drug.
  • Has initiated treatment with study medications within 1 month prior to study drug administration that can impact pain control.
  • Has taken any NSAIDs within least 10 days prior to the scheduled surgery.
  • Has current significant placental abnormality/complications including, but not limited to, placenta previa or placenta accreta.
  • Has a medical condition such that, in the opinion of the Investigator, participating in the study would pose a health risk to the subject or confound the postoperative assessments.
  • Has uncontrolled anxiety, psychiatric, or neurological disorder.
  • Had a malignancy in the last year, with the exception of nonmetastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.
  • Has a known or suspected history of drug abuse, a positive drug screen on the day of surgery, or a recent history of alcohol abuse.
  • Previously participated in an HTX-011 study.
  • Received an investigational product or device in a clinical trial within 30 days or within 5 elimination half-lives.
  • Weight is <50 kg at the time of Screening visit.
  • In the Investigator's judgment, subject is likely to have been morbidly obese prior to her pregnancy.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:非随机化
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:HTX-011 300 mg/9 mg

HTX-011 (bupivacaine/meloxicam) 300 mg/9 mg via instillation

bupivacaine/meloxicam extended-release solution for instillation use, supplied in commercially available ZYNRELEF kits

其他名称:
  • ZYNRELEF

ZYNRELEF kits include sterile, individually packaged components for administration, including vented vial spikes, Luer lock syringes, custom Luer lock applicators, and syringe tip caps.

实验性的:HTX-011 400 mg/12 mg + MMA

HTX-011 (bupivacaine/meloxicam) 400 mg/12 mg via instillation + oral (PO) non-opioid multimodal analgesic (MMA) regimen

bupivacaine/meloxicam extended-release solution for instillation use, supplied in commercially available ZYNRELEF kits

其他名称:
  • ZYNRELEF

ZYNRELEF kits include sterile, individually packaged components for administration, including vented vial spikes, Luer lock syringes, custom Luer lock applicators, and syringe tip caps.

PO ibuprofen 400 mg every 6 hours (q6h), alternating with PO acetaminophen 975 mg to 1 g q6h, alternating the 2 medications so that an analgesic was taken approximately every 3 hours (q3h) while the subject was awake

其他名称:
  • ibuprofen, acetaminophen

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Bupivacaine Plasma Cmax
大体时间:Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)

Maximum plasma concentration of bupivacaine

Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
Bupivacaine Plasma Tmax
大体时间:Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)

Time to maximum concentration of bupivacaine in plasma

Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
Bupivacaine Plasma t1/2
大体时间:Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)

Half life of bupivacaine in plasma

Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
Bupivacaine Plasma AUCinf
大体时间:Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)

Area under the bupivacaine plasma concentration-time curve from Time 0 extrapolated to infinity

Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
Bupivacaine Breast Milk Cmax
大体时间:Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)

Maximum concentration of bupivacaine in breast milk

Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
Bupivacaine Breast Milk Tmax
大体时间:Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)

Time to maximum concentration of bupivacaine in breast milk

Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
Bupivacaine Breast Milk AUClast
大体时间:Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)

Area under the bupivacaine breast milk concentration-time curve from Time 0 to time of last quantifiable concentration

Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
Meloxicam Plasma Cmax
大体时间:Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)

Maximum plasma concentrations of meloxicam

Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
Meloxicam Plasma Tmax
大体时间:Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)

Time to maximum meloxicam plasma concentration in plasma

Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
Meloxicam Plasma t1/2
大体时间:Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)

Half-life of meloxicam in plasma

Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
Meloxicam Plasma AUCinf
大体时间:Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)

Area under the meloxicam plasma concentration-time curve from Time 0 extrapolated to infinity

Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
Meloxicam Breast Milk Cmax
大体时间:Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)

Maximum concentration of meloxicam in breast milk

Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
Meloxicam Breast Milk Tmax
大体时间:Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)

Time to maximum meloxicam concentration in breast milk

Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)
Meloxicam Breast Milk AUClast
大体时间:Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)

Area under the meloxicam breast milk concentration-time curve from Time 0 to time of last quantifiable concentration

Day 1 to Day 16 for Cohort 1 (HTX-011 300 mg/9 mg); Day 1 to Day 11 for Cohort 2 (HTX-011 400 mg/12 mg + MMA)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2019年6月24日

初级完成 (实际的)

2021年12月3日

研究完成 (实际的)

2021年12月27日

研究注册日期

首次提交

2019年5月9日

首先提交符合 QC 标准的

2019年5月16日

首次发布 (实际的)

2019年5月20日

研究记录更新

最后更新发布 (实际的)

2026年11月13日

上次提交的符合 QC 标准的更新

2026年10月29日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅